Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cytokinetics (CYTK) Return on Capital Employed: 2009-2025

Historic Return on Capital Employed for Cytokinetics (CYTK) over the last 14 years, with Sep 2025 value amounting to -0.48%.

  • Cytokinetics' Return on Capital Employed fell 10.00% to -0.48% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.48%, marking a year-over-year decrease of 10.00%. This contributed to the annual value of -0.57% for FY2024, which is 3.00% up from last year.
  • Latest data reveals that Cytokinetics reported Return on Capital Employed of -0.48% as of Q3 2025, which was up 1.88% from -0.49% recorded in Q2 2025.
  • Cytokinetics' 5-year Return on Capital Employed high stood at -0.20% for Q1 2021, and its period low was -0.73% during Q4 2023.
  • Its 3-year average for Return on Capital Employed is -0.54%, with a median of -0.48% in 2025.
  • In the last 5 years, Cytokinetics' Return on Capital Employed slumped by 47bps in 2023 and then spiked by 34bps in 2024.
  • Over the past 5 years, Cytokinetics' Return on Capital Employed (Quarterly) stood at -0.24% in 2021, then declined by 9bps to -0.34% in 2022, then plummeted by 39bps to -0.73% in 2023, then climbed by 30bps to -0.43% in 2024, then dropped by 10bps to -0.48% in 2025.
  • Its Return on Capital Employed stands at -0.48% for Q3 2025, versus -0.49% for Q2 2025 and -0.48% for Q1 2025.